- Home
- HCKT vs ZNTL Comparison
HCKT vs ZNTL Comparison
Compare HCKT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | ZNTL |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 289.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HCKT | ZNTL |
|---|---|---|
| Price | $13.40 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $17.33 | $7.44 |
| AVG Volume (30 Days) | 234.4K | ★ 1.4M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $27.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.16 | $1.28 |
| 52 Week High | $20.68 | $6.95 |
Technical Indicators
Market Signals| Indicator | HCKT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 31.46 |
| Support Level | $12.39 | $1.63 |
| Resistance Level | $14.50 | $2.76 |
| Average True Range (ATR) | 0.51 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 54.33 | 12.30 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.